RTP Mobile Logo
Select Publications

Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4(4):486-501. Abstract

Conteduca V et al. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol 2018;36(5):240.e1-240.e11. Abstract

De Nunzio C et al. Adverse events related to abiraterone and enzalutamide treatment: Analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer Prostatic Dis 2020;23(2):199-206. Abstract

Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377(9768):813-22. Abstract

Hu J-R et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: Contemporary meta-analyses. Arterioscler Thromb Vasc Biol 2020;40:e55-e64. Abstract

Hussain A et al. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020;[Online ahead of print]. Abstract

Iacovelli R et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16(3):e645-53. Abstract

Lu-Yao G et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020;77(2):158-66. Abstract

Rice MA et al. Second-generation antiandrogens: From discovery to standard of care in castration resistant prostate cancer. Front Oncol 2019;9:801. Abstract

Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68. Abstract

Smith MR et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745-75. Abstract

Thiery-Vuillemin A et al. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: Initial results from the observational AQUARiUS study. ESMO Open 2018;3(5):e000397. Abstract

van Staa TP et al. Epidemiology of fractures in England and Wales. Bone 2001;29(6):517-22. Abstract